Company news

LivaNova PLC news in 2025

LivaNova PLC's news releases, calls and decks from 2025, newest first.

View company

LivaNova to Present at J.P. Morgan Healthcare Conference in January

December 22, 2025

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

December 2, 2025

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

December 1, 2025

LivaNova to Present at Piper Sandler Healthcare Conference in December

November 24, 2025

LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

November 23, 2025

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

November 11, 2025

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

November 4, 2025

LivaNova to Present at Wolfe Research Healthcare Conference in November

October 22, 2025

LivaNova to Announce Third-Quarter 2025 Results

October 7, 2025

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

October 6, 2025

LivaNova Appoints Donald Zurbay as a New Director

September 3, 2025

LivaNova to Host Investor Day on November 12, 2025

August 24, 2025

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

August 21, 2025

LivaNova Launches Essenz Perfusion System in China

August 17, 2025

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

August 5, 2025

LivaNova to Announce Second-Quarter 2025 Results

July 8, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

June 4, 2025

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

June 4, 2025

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

June 3, 2025

LivaNova to Present at the Jefferies Global Healthcare Conference

May 14, 2025

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

May 6, 2025

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

May 6, 2025

LivaNova to Announce First-Quarter 2025 Results

March 25, 2025

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

February 24, 2025

LivaNova to Present at the Barclays Global Healthcare Conference

February 20, 2025

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

January 20, 2025

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

January 5, 2025

Calls in 2025

Decks in 2025